Persistence of Risk for Type 2 Diabetes After Gestational Diabetes Mellitus
Diaz-Santana M, O’Brien K, Mark Park Y, Sandler D and Weinberg C
Diabetes Care 2022;45(4):864–870
https://doi.org/10.2337/dc21-1430
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
Stefan N and Cusi K
Lancet Diabetes and Endocrinology 2022: 10 (4): 284-296
DOI:https://doi.org/10.1016/S2213-8587(22)00003-1
Beliefs Around Hypoglycemia and Their Impacts on Hypoglycemia Outcomes in Individuals with Type 1 Diabetes and High Risks for Hypoglycemia Despite Using Advanced Diabetes Technologies
Lin Y, Richardson C, Dobrin J, DeJonckheere M, Mizokami-Stout K, Fetters M et al
Diabetes Care 2022;45(3):520–528
https://doi.org/10.2337/dc21-1285
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 DiabetesThe SURPASS-5 Randomized Clinical Trial
Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H et al
JAMA. 2022;327(6):534-545.
doi:10.1001/jama.2022.0078
Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research’s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases
Cefalu T, Andersen D, Arreaza Rubin G, Pin C, Sato S, Verchere B et al
Diabetes 2022:71:1-22
https://doi.org/10.2337/db21-0777
Standards of Medical Care in Diabetes-2022
Diabetes Care 2022;45(Supplement)
https://doi.org/10.2337/dc22-Sint
Comentarios recientes